ATAI:NSD-ATAI Life Sciences N.V. Common Shares (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.97

Change

+0.05 (+1.28)%

Market Cap

USD 0.63B

Volume

0.47M

Avg Analyst Target

USD 32.33 (+714.44%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

ATAI Life Sciences N.V. Common Shares (ATAI) Stock Analysis:
Based on the ATAI Life Sciences N.V. Common Shares stock forecasts from 3 analysts, the average analyst target price for ATAI Life Sciences N.V. Common Shares is USD 32.33 over the next 12 months. ATAI Life Sciences N.V. Common Shares’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ATAI Life Sciences N.V. Common Shares is Bullish , which is based on 7 positive signals and 3 negative signals. At the last closing, ATAI Life Sciences N.V. Common Shares’s stock price was USD 3.97. ATAI Life Sciences N.V. Common Shares’s stock price has changed by +22.15% over the past week, -23.51% over the past month and +146.58% over the last year.

About

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PC ...Read More

Company Website : https://www.atai.life

Address : Krausenstrasse 9-10, Berlin, Germany, 10117

Employees : 87

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.82

52 Week High : 22.91

Short Ratio : 3.98

52 Week Low : 3.05

Shorted Shares : 3,254,020

200 Day Moving Average : 9.57

Shorted Shares Previous Month : 2,927,567

50 Day Moving Average : 4.76

Shares Held By Insiders : 10.22%

Short Percentage : 2.57%

Shares Held by Institutions : 27.75%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-2.05 (-0.31%)

 USD71.36B 9.16 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+3.10 (+1.23%)

 USD64.54B 26.63 18.23
MRNA Moderna Inc

+5.67 (+4.12%)

 USD54.78B 4.05 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

+10.81 (+6.88%)

 USD36.74B 3.67 1.75
SGEN Seagen Inc

-0.37 (-0.26%)

 USD26.32B 55.02 44.86
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
GMAB Genmab A/S

+0.84 (+2.84%)

 USD19.31B 46.16 5.06
ARGX argenx SE

+15.26 (+5.01%)

 USD17.59B N/A N/A
INCY Incyte Corporation

+0.95 (+1.29%)

 USD16.26B 17.19 22.08

ETFs Containing ATAI

Symbol Name Weight Mer Price(Change) Market Cap
PSY Defiance Next Gen Altered.. 0.00 % 0.75 %

+0.12 (+2.23%)

 N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.97% 46% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.97% 46% F 25% F
Trailing 12 Months  
Capital Gain 146.58% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 146.58% 99% A+ 99% A+
Trailing 5 Years  
Capital Gain 11.20% 73% C 54% F
Dividend Return 178.43% 100% A+ 100% A+
Total Return 189.64% 88% B+ 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 125.79% 92% A- 95% A
Dividend Return 30.00% 80% B- 100% A+
Total Return 155.79% 93% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 308.53% 7% F 4% F
Risk Adjusted Return 50.50% 88% B+ 78% C+
Market Capitalization 0.63B 79% C+ 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.30 77% C+ 94% A
Price/Book Ratio 1.55 54% F 52% F
Price / Cash Flow Ratio -9.96 80% B- 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -72.40% 38% F 17% F
Return on Invested Capital -59.40% 45% F 17% F
Return on Assets -28.61% 43% F 13% F
Debt to Equity Ratio 0.20% 88% B+ 90% A-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.98 58% F 41% F
Short Percent 2.57% 68% D+ 53% F
Beta 2.82 3% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector